These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15648057)

  • 1. [18F]FDOPA PET and clinical features in parkinsonism due to manganism.
    Racette BA; Antenor JA; McGee-Minnich L; Moerlein SM; Videen TO; Kotagal V; Perlmutter JS
    Mov Disord; 2005 Apr; 20(4):492-496. PubMed ID: 15648057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic utility of positron emission tomography for parkinsonism after chronic manganese exposure].
    Abe Y; Kachi T; Kato T; Ito K; Yanagisawa N; Sobue G
    Rinsho Shinkeigaku; 1999 Jul; 39(7):693-9. PubMed ID: 10548904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manganese-induced parkinsonism and Parkinson's disease.
    Olanow CW
    Ann N Y Acad Sci; 2004 Mar; 1012():209-23. PubMed ID: 15105268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiopathic parkinsonism with superimposed manganese exposure: utility of positron emission tomography.
    Kim Y; Kim JW; Ito K; Lim HS; Cheong HK; Kim JY; Shin YC; Kim KS; Moon Y
    Neurotoxicology; 1999; 20(2-3):249-52. PubMed ID: 10385888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [
    El Ouartassi A; Giordana C; Schiazza A; Chardin D; Darcourt J
    Brain Imaging Behav; 2023 Dec; 17(6):619-627. PubMed ID: 37474673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease.
    Gallagher CL; Johnson SC; Bendlin BB; Chung MK; Holden JE; Oakes TR; Brooks BR; Konopacki RA; Dogan S; Abbs JH; Xu G; Nickles RJ; Pyzalski RW; Dejesus OT; Brown WD
    Brain Imaging Behav; 2011 Sep; 5(3):203-11. PubMed ID: 21556744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [
    Criswell SR; Nielsen SS; Warden M; Perlmutter JS; Moerlein SM; Flores HP; Huang J; Sheppard L; Seixas N; Checkoway H; Racette BA
    Neurotoxicology; 2018 Jan; 64():43-49. PubMed ID: 28694016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]fluorodopa.
    Boecker H; Weindl A; Leenders K; Antonini A; Kuwert T; Kruggel F; Grafin von Einsiedel H; Conrad B
    Acta Neurol Scand; 1996 Jun; 93(6):387-92. PubMed ID: 8836298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.
    Eidelberg D; Moeller JR; Dhawan V; Sidtis JJ; Ginos JZ; Strother SC; Cedarbaum J; Greene P; Fahn S; Rottenberg DA
    Mov Disord; 1990; 5(3):203-13. PubMed ID: 2117706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced uptake of FDOPA PET in end-stage liver disease with elevated manganese levels.
    Criswell SR; Perlmutter JS; Crippin JS; Videen TO; Moerlein SM; Flores HP; Birke AM; Racette BA
    Arch Neurol; 2012 Mar; 69(3):394-7. PubMed ID: 22410448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.
    Li CT; Palotti M; Holden JE; Oh J; Okonkwo O; Christian BT; Bendlin BB; Buyan-Dent L; Harding SJ; Stone CK; DeJesus OT; Nickles RJ; Gallagher CL
    Synapse; 2014 Aug; 68(8):325-31. PubMed ID: 24710997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnosis of manganese-induced parkinsonism.
    Cersosimo MG; Koller WC
    Neurotoxicology; 2006 May; 27(3):340-6. PubMed ID: 16325915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neuropathology of manganese-induced Parkinsonism.
    Perl DP; Olanow CW
    J Neuropathol Exp Neurol; 2007 Aug; 66(8):675-82. PubMed ID: 17882011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology of parkinsonism due to hydrocephalus.
    Racette BA; Esper GJ; Antenor J; Black KJ; Burkey A; Moerlein SM; Videen TO; Kotagal V; Ojemann JG; Perlmutter JS
    J Neurol Neurosurg Psychiatry; 2004 Nov; 75(11):1617-9. PubMed ID: 15489399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of susceptibility-weighted imaging for differentiating Parkinsonism-predominant multiple system atrophy from Parkinson's disease: correlation with 18F-flurodeoxyglucose positron-emission tomography.
    Yoon RG; Kim SJ; Kim HS; Choi CG; Kim JS; Oh J; Chung SJ; Lee CS
    Neurosci Lett; 2015 Jan; 584():296-301. PubMed ID: 25450142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
    Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of familial juvenile dystonia-parkinsonism: 18F-6-fluorodopa and 18F-fluoro-2-deoxyglucose PET study].
    Hanakawa T; Fukuyama H; Akiguchi I; Kato M; Kimura J; Shibasaki H
    Rinsho Shinkeigaku; 1996 May; 36(5):655-60. PubMed ID: 8905984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic correlates of metabolic network activity in Parkinson's disease.
    Holtbernd F; Ma Y; Peng S; Schwartz F; Timmermann L; Kracht L; Fink GR; Tang CC; Eidelberg D; Eggers C
    Hum Brain Mapp; 2015 Sep; 36(9):3575-85. PubMed ID: 26037537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.